Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Stockholm, December 18, 2023: Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on October 12. Anders Edvell, CEO of Immedica comments: “Today’s approval marks a major milestone for Immedica, but an even greater one for the people living with ARG1-D and